Search Result

Isoforms Recommended:	ErbB2/HER2

Results for "

HER2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (3) ADC Cytotoxin (3) ADC Linker (1) Akt (10) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (10) Apoptosis (24) Autophagy (12) Bacterial (2) Bcl-2 Family (1) Biochemical Assay Reagents (2) BRK (1) Btk (5) c-Met/HGFR (7) Calcium Channel (2) Caspase (1) CDK (17) COX (1) CXCR (1) Dihydrofolate reductase (DHFR) (3) Drug-Linker Conjugates for ADC (6) EGFR (146) Epigenetic Reader Domain (1) ERK (5) Estrogen Receptor/ERR (6) Fatty Acid Synthase (FASN) (2) HDAC (1) HSP (13) IGF-1R (1) Interleukin Related (1) IRAK (2) Isotope-Labeled Compounds (2) Itk (1) JAK (1) JNK (1) Ligands for Target Protein for PROTAC (1) Mitochondrial Metabolism (1) Mitophagy (1) MMP (2) Monoamine Oxidase (2) mTOR (2) NAMPT (1) Necroptosis (1) NF-κB (1) NO Synthase (1) p38 MAPK (5) PARP (2) PD-1/PD-L1 (1) PDGFR (3) PI4K (1) Potassium Channel (1) PROTACs (5) Radionuclide-Drug Conjugates (RDCs) (4) Raf (1) Reactive Oxygen Species (3) STING (1) Survivin (2) Thymidylate Synthase (2) TNF Receptor (2) Toll-like Receptor (TLR) (5) Topoisomerase (4) Trk Receptor (1) VEGFR (6) Wnt (1)
By Research Areas:	Cancer (213) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (11) Neurological Disease (3)
Click Chemistry:	TCO (1) Azide (1) Alkynes (1)
Oligonucleotides:	Antisense Oligonucleotides (1)

216

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143734

HER2-IN-6	EGFR	Cancer
HER2-IN-6 is a potent inhibitor of *HER2. HER2-IN-6 has the potential for the research of wild and/or mutant EGFR and/or HER2* kinase mediated tumor (extracted from patent WO2021164697A1, compound 11) .

HY-143874

HER2-IN-7	EGFR	Cancer
HER2-IN-7 is a potent inhibitor of *HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2*), including cancer (extracted from patent WO2019214634A1, compound 23) .

HY-143323

HER2-IN-9	EGFR	Cancer
HER2-IN-9 is an orally active *HER2* inhibitor, with an IC₅₀ value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers .

HY-151162

HER2-IN-12	EGFR	Cancer
HER2-IN-12 is a *HER2* inhibitor (IC₅₀: 121 nM). HER2-IN-12 can be used in the research of cancers, such as breast cancer .

HY-163417

HER2-IN-15	EGFR	Cancer
HER2-IN-15 (Compound 1) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-15 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163418

HER2-IN-17	EGFR	Cancer
HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163420

HER2-IN-16	EGFR	Cancer
HER2-IN-16 (Compound 14) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-16 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163657

HER2-IN-20	EGFR	Cancer
HER2-IN-20 (compound 32) is a potent and selective HER2 ^WT and HER2 ^YVMA inhibitor with IC₅₀ values of 49, 42 nM, respectively. HER2-IN-20 has the potential for the research of non-small cell lung cancer (NSCLC) .

HY-144097

HER2-IN-8	EGFR	Inflammation/Immunology Cancer
HER2-IN-8 is a *HER-2* inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation .

HY-151118

HER2-IN-11	Apoptosis	Cancer
HER2-IN-11 is a psoralen derivative. HER2-IN-11 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-11 induces apoptosis .

HY-151116

HER2-IN-10	Apoptosis	Cancer
HER2-IN-10 is a psoralen derivative. HER2-IN-10 has anti-breast cancer activity and light-activated cytotoxicity. HER2-IN-10 induces apoptosis .

HY-153557

HER2-IN-13	EGFR Potassium Channel	Cancer
HER2-IN-13 (Compound 33) is an *HER2* inhibitor with an IC₅₀ of 8 nM. HER2-IN-13 also inhibits wt-EGFR with an IC₅₀ of 0.40 μM .

HY-153557A

HER2-IN-14	EGFR	Cancer
HER2-IN-14 (Compound 34) is an *HER2* inhibitor with an IC₅₀ of 18 nM. HER2-IN-14 also inhibits wt-EGFR with an IC₅₀ of 6.3 μM .

HY-163419

HER2-IN-18	EGFR	Cancer
HER2-IN-18 is a *HER2* inhibitor, with an IC₅₀ less than 200 nM for HER-YVMA and HER-WT. HER2-IN-18 can be used for cancer research .

HY-143733

HER2-IN-5	EGFR	Cancer
HER2-IN-5 is a potent and orally active *HER-2* inhibitor, example 10, extracted from patent WO2021164697 .

HY-163453

HER2-IN-19	EGFR	Cancer
HER2-IN-19 (Compound 10e) is a potent inhibitor of *HER2* and EGFR with IC₅₀ values of 0.87 respectively and 3.5 nM. HER2-IN-19 has potent inhibitory activity against tumor cells, IC₅₀ ^NCI-N87 = 1.63 nM, IC₅₀ ^BT474= 15.17 nM, IC₅₀ ^{BaF3-HER2YVMA} = 1.49 nM .

HY-P10648

Herceptide HER2-targeting peptide	EGFR	Cancer
Herceptide (HER2-targeting peptide) is a *HER2*-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-P4082

ErbB-2-binding peptide HER2-binding peptide	EGFR	Cancer
ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide has the potential for cancer research .

HY-P10569

*Biotin HER-2* substrate peptide**	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-P9907

Trastuzumab 25+ Cited Publications Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9907A

*Trastuzumab (anti-HER2)* 25+ Cited Publications Anti-Human HER2, Humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-147797

*EGFR/HER2/CDK9-IN-2*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity .*

HY-147798

*EGFR/HER2/CDK9-IN-3*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-3 (Compound 10) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 191.08, 132.65, and 113.98 nM, respectively. EGFR/HER2/CDK9-IN-3 exhibits remarkable antitumor activity .*

HY-147796

*EGFR/HER2/CDK9-IN-1*	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 90.17, 131.39, and 67.04 nM, respectively. EGFR/HER2/CDK9-IN-1 exhibits remarkable antitumor activity .*

HY-147992

*EGFR/HER2-IN-4*	EGFR	Cancer
EGFR/HER2-IN-4(compound 6d) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-4 inhibits EGFR with an IC₅₀ value of 0.6 nM and demonstrates potent EGFR kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-4 has potent antitumor efficacy in vivo and can be used for lung cancer research .

HY-147994

*EGFR/HER2-IN-5*	EGFR	Cancer
EGFR/HER2-IN-5 (compound 6h) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-5 inhibits EGFR with an IC₅₀ value of 1.01 nM and demonstrates potent EGFR kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-5 has potent antitumor efficacy in vivo and can be used for lung cancer research .

HY-P9912A

*Pertuzumab (anti-HER2)*	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-162623

*EGFR/HER2-IN-15*	EGFR	Cancer
EGFR/HER2-IN-15, a dihydropyrimidine, is a potent *EGFR/HER2* inhibitor. EGFR/HER2-IN-15 significantly inhibits EGFR ^wt activity with an IC₅₀ of 37.21 nM. EGFR/HER2-IN-15 has anticaner effects .

HY-157399

*EGFR/HER2-IN-10*	EGFR	Cancer
EGFR/HER2-IN-10 (compound 9F) is a potent and selective dual *EGFR/HER2* inhibitor with IC₅₀s of 2.3 nM and 234 nM for EGFR and HER2, respectively. EGFR/HER2-IN-10 shows an effective antiproliferative action against prostate carcinoma .

HY-151161

*EGFR/HER2-IN-8*	EGFR	Cancer
EGFR/HER2-IN-8 (compound 34) is a *EGFR/HER2* and DHFR inhibitor. EGFR/HER2-IN-8 inhibits EGFR kinase, HER2 kinase and DHFR with IC₅₀s of 0.45, 0.244 and 5.669 μM, respectively. EGFR/HER2-IN-8 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .

HY-151156

*EGFR/HER2-IN-6*	EGFR Apoptosis	Cancer
EGFR/HER2-IN-6 (compound 43) is an *EGFR/HER2* and DHFR inhibitor. EGFR/HER2-IN-6 inhibits EGFR kinase, HER2 kinase and DHFR with IC₅₀s of 0.122, 0.078 and 0.585 μM, respectively. EGFR/HER2-IN-6 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .

HY-115951

*EGFR/HER2-IN-2*	EGFR	Cancer
EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual inhibitor of EGFR and *HER2* with IC₅₀ values of 5.02 µM and 0.83 µM against EGFR and HER2, respectively .

HY-115952

*EGFR/HER2-IN-3*	EGFR	Cancer
EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual inhibitor of EGFR and *HER2* .

HY-153111

*EGFR/HER2-IN-9*	EGFR	Cancer
EGFR/HER2-IN-9 (Compound 1) is an EGFR and *HER2* inhibitor with IC₅₀s of 3.2, 8.3 and 14 nM against EGFR, EGFR T790M and HER2, respectively .

HY-151158

*EGFR/HER2-IN-7*	EGFR	Cancer
EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2-IN-7 is a *EGFR/HER2* kinase and DHFR inhibitor, with IC₅₀s of 0.18 μM (EGFR), 0.146 μM (HER2), respectively. EGFR/HER2-IN-7 shows moderate inhibition on DHFR (IC₅₀=0.907 μM) .

HY-146238

*EGFR/HER2/TS-IN-1*	EGFR Thymidylate Synthase Apoptosis	Cancer
EGFR/HER2/TS-IN-1 (Compound 4d) is an EGFR, *HER2* and TS (Thymidylate synthase) inhibitor with IC₅₀ values of 0.203, 0.088 and 0.168 μM against EGFR, HER2 and TS, respectively. EGFR/HER2/TS-IN-1 induces MCF7 cell apoptosis .

HY-160682

*EGFR/HER2-IN-12*	EGFR	Others
EGFR/HER2-IN-12 (compound 14b) is a dual inhibitor of EGFR and HER2 with 81% and 51% inhibition at 10 μM. The toxicity of EGFR/HER2-IN-12 to cancer cells A431 and MDA-MB-361 was not significant .

HY-161602

*EGFR/HER2-IN-13*	EGFR	Cancer
EGFR/HER2-IN-13 (Compd 38) is an inhibitor of mutant EGFR/HER2s which are resistant to other drugs. EGFR/HER2-IN-13 can be used for cancer research .

HY-161603

*EGFR/HER2-IN-14*	EGFR	Cancer
EGFR/HER2-IN-14 (Compd 46) is an inhibitor of mutant EGFR/HER2s which are resistant to other drugs. EGFR/HER2-IN-14 can be used for cancer research .

HY-159519

*EGFR/HER2-IN-16*	Apoptosis EGFR	Cancer
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

HY-149633

*EGFR/HER2/DHFR-IN-3*	EGFR Dihydrofolate reductase (DHFR) Apoptosis	Cancer
EGFR/HER2/DHFR-IN-3 (compound 4c) is a potent dual inhibitor of *EGFR/HER2, with IC₅₀s of 0.138 and 0.092 μM, respectively. EGFR/HER2/DHFR-IN-3 also inhibits DHFR, with an IC₅₀* of 0.193 M. EGFR/HER2/DHFR-IN-3 causes arrest at the S phase of the cell cycle and induces apoptosis in MCF7 breast cancer cells .

HY-151154

*EGFR/HER2/DHFR-IN-1*	EGFR	Cancer
EGFR/HER2/DHFR-IN-1 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2/DHFR-IN-1 is a multiple inhibitor of *EGFR/HER2* kinase and DHFR, with IC₅₀s of 0.153 μM, 0.108 μM, 0.291 μM, respectively. EGFR/HER2/DHFR-IN-1 arrests cell cycle at G1/S and induces cells apoptosis .

HY-160613

*EGFR/HER2-IN-11*	EGFR	Cancer
EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC₅₀s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI₅₀ of 601 nM .

HY-146239

*EGFR/HER2/TS-IN-2*	EGFR Thymidylate Synthase	Cancer
EGFR/HER2/TS-IN-2 (compound 17) is a potent *EGFR/HER2* and TS (Thymidylate synthase) inhibitor, with IC₅₀ values of 0.173, 0.125, and 1.12 μM, respectively. EGFR/HER2/TS-IN-2 shows cytotoxic activity against MDA-MB-231 cancer cell lines, with an IC₅₀ of 1.69 µM .

HY-149632

*EGFR/HER2/DHFR-IN-2*	EGFR Dihydrofolate reductase (DHFR)	Cancer
EGFR/HER2/DHFR-IN-2 (Compound 4b) is an inhibitor of EGFR, *HER2, and DHFR* (IC₅₀: 0.248, 0.156, 0.138 μM respectively). EGFR/HER2/DHFR-IN-2 has anticancer activities against a panel of cancer cells (IC₅₀: 9.14, 7.33, 14.18, 24.87, 20.07, 6.16 μM for Hep G2, HeLa, HEp-2, HCT 116, PC-3, MCF7 cells). EGFR/HER2/DHFR-IN-2 reduce breast cancer tumor growth .

HY-164763

SHR-A1201	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
SHR-A1201 is a *HER2*-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .

HY-164762

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a *HER2*-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-138298A

Trastuzumab deruxtecan 2 Publications Verification DS-8201; DS-8201a	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-*human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2* antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer ^[2].

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library

2,805 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 2,805 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

HY-L177

Antibody Inhibitor Library

927 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 927 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

HY-L184

Anti-Gastric Cancer Compound Library

655 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 655 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

HY-L074

Anti-Breast Cancer Compound Library

2,049 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,049 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-W016412

Coenzyme Q0

2 Publications Verification

CoQ0

Enzyme Substrates

Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling ^[2] .

HY-W088413A

DOTA-amide dihydrate	Chelators
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to *HER2* and can be used to detect bone metastases, which are common in prostate cancer .

HY-W283556

DO2A-tert-butyl ester	Chelators
DO2A-tert-butyl ester is a bifunctional chelator (BFC) that can be used for the coupling of peptides and radionuclides. DO2A-tert-butyl ester can be used in the development of radionuclide imaging tracers .

Cat. No.	Product Name	Target	Research Area

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-P4082

ErbB-2-binding peptide HER2-binding peptide	EGFR	Cancer
ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide has the potential for cancer research .

HY-P10648

Herceptide HER2-targeting peptide	EGFR	Cancer
Herceptide (HER2-targeting peptide) is a *HER2*-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .

HY-P10569

*Biotin HER-2* substrate peptide**	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-P5744

SPPHPSPAFSPAFDNLYYWDQ	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743

IRGRILHDGAYSLTLQGLGIH	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH can be used for the research class II HER2-DC1 vaccine studies .

HY-P5744A

SPPHPSPAFSPAFDNLYYWDQ TFA	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ TFA is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743A

IRGRILHDGAYSLTLQGLGIH TFA	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH TFA is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-106204

Nelipepimut-S	EGFR	Cancer
Nelipepimut-S is a peptide vaccine which targets *HER2. Nelipepimut-S has immune activity against HER2* positive breast cancer .

HY-P5742

ELAAWCRWGFLLALLPPGIAG	Peptides	Cancer
ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	Peptides	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5745

TYVPANASL	Peptides	Cancer
TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine .

HY-P5745A

TYVPANASL TFA	Peptides	Cancer
TYVPANASL TFA is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL TFA can be used to prepare J-LEAPS vaccine .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research ^[2] .

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research ^[2] .

Cat. No.	Product Name	Target	Research Area

HY-P9907

Trastuzumab Maximum Cited Publications 29 Publications Verification Anti-Human HER2, Humanized Antibody	Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9907A

*Trastuzumab (anti-HER2)* Maximum Cited Publications 29 Publications Verification Anti-Human HER2, Humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9912A

*Pertuzumab (anti-HER2)*	EGFR	Cancer
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P99896

Runimotamab	Inhibitory Antibodies	Others Cancer
Runimotamab is an IgG1-κ humanized chimeric antibody targeting CD3E and HER2 .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity *CD137/HER2* bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research ^[2].

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Inflammation/Immunology Cancer
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both *HER2* and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .

HY-P99437

Anbenitamab 1 Publications Verification KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human *HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2* signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research ^[2].

HY-P9912

Pertuzumab 5+ Cited Publications	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a *HER2* dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P990238

*Anti-Human/Rat HER2* (neu) Antibody (7.16.4)**	Inhibitory Antibodies	Others
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to human/rat HER2.

HY-P99630

Gancotamab MM-302	EGFR	Cancer
Gancotamab (MM-302) is a *HER2*-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting *HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)*) .

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	EGFR	Cancer
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of *HER2* and *HER3* .

HY-P99969

Inetetamab	EGFR	Cancer
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities ^[2].

HY-P99380

Zanidatamab 1 Publications Verification ZW 25	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct *HER2* epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to *FZD1/2/5/7/8* receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma ^[2] .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, *HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

Species:	Human (15) Rhesus Macaque (2) Rat (4) Mouse (3) Cynomolgus (3) Canine (1)
Tag:	His (18) Tag Free (2) Avi (5) Fc (8)
Source:	HEK293 (27) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P78882

	Her2/CD340 Protein, Human (Biotinylated, HEK293, His) ERBB2; CD340; HER-2; neu; HER2; MLN19; NEU; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. Her2/CD340 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Her2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P74895

	HER2/CD340 Protein, Rat (HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Rat	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics.Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability.HER2/CD340 Protein, Rat (HEK293, His) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P74897

	HER2/CD340 Protein, Canine (HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Canine	HEK293
	The HER2/CD340 Protein is a member of the receptor tyrosine kinase family. HER2/CD340 Protein participates in the PI3K/Akt signaling pathway to regulate the differentiation and apoptosis of neural stem cells in the cochlear nucleus. HER2/CD340 Protein is an overexpressed oncogenic factor in bladder cancer that activates the oncogenic signaling pathway, thereby promoting tumor cell survival/proliferation. HER2/CD340 Protein, Canine (HEK293, His) is the recombinant canine-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag. The total length of HER2/CD340 Protein, Canine (HEK293, His) is 630 a.a., with molecular weight of 75- 95 kDa.

HY-P77535

	HER2/CD340 Protein, Human (Biotinylated, Domain 4, HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, Domain 4, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P78680

	HER2/CD340 Protein, Human (S310Y, HEK293, His) ERBB2; CD340; HER-2/neu; HER2; MLN19; NEU; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (S310Y, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag and S310Y, , , , mutation.

HY-P73094

	HER2/CD340 Protein, Human (HEK293) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with tag free.

HY-P74896

	HER2/CD340 Protein, Rat (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Rat	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics.Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability.HER2/CD340 Protein, Rat (HEK293, Fc) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77533

	HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P700887

	HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; NGL; TKR1; ERBB2; NEU; ENV; ENVW; ERVWE1; HERV7Q; HERVW	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag. The total length of HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) is 630 a.a., with molecular weight of 85-105 kDa.

HY-P73097

	HER2/CD340 Protein, Rat (HEK293) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Rat	HEK293
	The HER2/CD340 Protein is a member of the receptor tyrosine kinase family.HER2/CD340 Protein participates in the PI3K/Akt signaling pathway to regulate the differentiation and apoptosis of neural stem cells in the cochlear nucleus.HER2/CD340 Protein is an overexpressed oncogenic factor in bladder cancer that activates the oncogenic signaling pathway, thereby promoting tumor cell survival/proliferation.HER2/CD340 Protein, Rat (HEK293) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with tag free.

HY-P73929

	HER2/CD340 Protein, Mouse (HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, His) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag. The total length of HER2/CD340 Protein, Mouse (HEK293, His) is 631 a.a., with molecular weight of 100-110 kDa.

HY-P73930

	HER2/CD340 Protein, Mouse (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of HER2/CD340 Protein, Mouse (HEK293, Fc) is 631 a.a., with molecular weight of 120-130 kDa.

HY-P73929A

	HER2/CD340 Protein, Mouse (HEK293, N-His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Mouse	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Mouse (HEK293, N-His) is the recombinant mouse-derived HER2/CD340 protein, expressed by HEK293 , with N-His labeled tag. The total length of HER2/CD340 Protein, Mouse (HEK293, N-His) is 631 a.a., with molecular weight of 80-100 kDa.

HY-P73095

	HER2/CD340 Protein, Human (Domain 4, HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (142a.a, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P73931

	HER2/CD340 Protein, Human (Biotinylated, 173a.a, HEK293, His) Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, 173a.a, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P78138

	HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P78451

	HER2/CD340 Protein, Human (HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P78453

	HER2/CD340 Protein, Human (Domain 4, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (142a.a, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P700643

	HER2/CD340 Protein, Human (Biotinylated, Domain 4, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, 142a.a, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-His, C-Avi labeled tag.

HY-P70759

	HER2/CD340 Protein, Human (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	HER2/CD340 Protein, Human (HEK293, Fc) is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, Fc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70254

	HER2/CD340 Protein, Human (HEK293, His) rHuReceptor tyrosine-protein kinase erbB-2/HER2, His; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72626

	HER2/CD340 Protein, Rat (His) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Rat	E. coli
	The HER2/CD340 protein is a key protein tyrosine kinase that is a component of multiple cell surface receptor complexes and requires coreceptors for ligand binding.Its interaction within the neuregulin-receptor complex depends on neuregulin, and GP30 emerges as a potential ligand.HER2/CD340 Protein, Rat (His) is the recombinant rat-derived HER2/CD340 protein, expressed by E.coli , with C-6*His labeled tag.

HY-P75804

	HER2/CD340 Protein, Cynomolgus (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75805

	HER2/CD340 Protein, Cynomolgus (HEK293, His) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag. The total length of HER2/CD340 Protein, Cynomolgus (HEK293, His) is 630 a.a., with molecular weight of ~80-100 kDa.

HY-P75806

	HER2/CD340 Protein, Rhesus Macaque (HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Rhesus Macaque	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75807

	HER2/CD340 Protein, Rhesus Macaque (HEK293, His) Receptor tyrosine-protein kinase erbB-2; p185neu; CD340; Erbb2; Neu	Rhesus Macaque	HEK293
	The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics. Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability. HER2/CD340 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag. The total length of HER2/CD340 Protein, Rhesus Macaque (HEK293, His) is 629 a.a., with molecular weight of ~90-110 kDa.

HY-P72374

	HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc-Avi) Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

HY-P701268

	*FITC-Labeled HER2/CD340 Protein, Human (HEK293, Fc)* ERBB2; CD340; HER-2; neu; HER2; MLN19; NEU; NGL; TKR1	Human	HEK293
	FITC-Labeled HER2/CD340 Protein, Human (HEK293, Fc) is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. FITC-Labeled HER2/CD340 Protein, Human (HEK293, Fc), expressed by HEK293 , with Fc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13631DS

Dxd-d5
Dxd-d₅ is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) [1].

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-32721S

Neratinib-d6
Neratinib-d₆ (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.

HY-10261S1

Afatinib-d4
Afatinib-d₄ is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

HY-10261AS

Afatinib-d6 dimaleate
Afatinib-d₆ (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80500

	HER2 Antibody	IHC-P, WB, ICC/IF	Human
	HER2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 138 kDa, targeting to HER2. It can be used for IHC-P,WB,ICC assays with tag free, in the background of Human.

HY-P80658

	HER2 Antibody (YA771) ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	HER2 Antibody (YA771) is a non-conjugated and Mouse origined monoclonal antibody about 138 kDa, targeting to HER2. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-10223

CUDC-101 5+ Cited Publications		Alkynes
CUDC-101 is a potent inhibitor of HDAC, EGFR, and *HER2* with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159519

*EGFR/HER2-IN-16*		Azide
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and *HER-2* (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

HY-154802

TCO-GK-PEG4-NHS ester		TCO
TCO-GK-PEG4-NHS ester is an ADC Linker, and can be used for synthesis of ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d. ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d binds with high affinity and immunoreactivity to *HER2* . TCO-GK-PEG4-NHS ester is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

Cat. No.	Product Name		Classification

HY-158828

SSO111 sodium		Antisense Oligonucleotides
SSO111 sodium, a 20mer fully modified antisense oligonucleotide, targets the oncogene?HER2. SSO111 sodium induces exon 15 skipping during splicing, leading to the generation of a novel mRNA transcript that excludes exon 15. SSO111 sodium downregulated *HER2* mRNA, which resulted in the inhibition of proliferation and induction of apoptosis in HER2-overexpressing tumor cells.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: